Evidence map›Paper›PMID 31420461›Full record

ArticleNeurology2019

Blood NfL: A biomarker for disease severity and progression in Parkinson disease.

Chin-Hsien Lin, Cheng-Hsuan Li, Kai-Chien Yang, Fang-Ju Lin, Chau-Chung Wu, Jen-Jie Chieh, Ming-Jang Chiu

Abstract read
PubMed Publisher
In one paragraph

Article in Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 3 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 3 syntheses or guidelines pooled it, 208 citations in OpenAlex.

  1. Pooled it
  2. Elevated neurofilament light chain (NfL) in blood and CSF as a biomarker for Parkinson's disease cognitive impairment: A meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chin-Hsien LinFrom the Department of Neurology (C.-H.L., C.-H.L., M.-J.C.), Department of Internal Medicine (K.-C.Y., C.-C.W.), and Department of Pharmacy (F.-J.L.), National Taiwan University Hospital, College of Medicine, National Taiwan University; Department of Pharmacology (K.-C.Y.), Graduate Institute of Clinical Pharmacy & School of Pharmacy (F.-J.L.), and Graduate Institute of Brain and Mind Sciences (M.-J.C.), College of Medicine, National Taiwan University; Institute of Electro-Optical Science and Technology (J.-J.C.), National Taiwan Normal University; and Graduate Institute of Biomedical Engineering and Bioinformatics (M.-J.C.) and Graduate Institute of Psychology (M.-J.C.), National Taiwan University, Taipei.
Cheng-Hsuan LiFrom the Department of Neurology (C.-H.L., C.-H.L., M.-J.C.), Department of Internal Medicine (K.-C.Y., C.-C.W.), and Department of Pharmacy (F.-J.L.), National Taiwan University Hospital, College of Medicine, National Taiwan University; Department of Pharmacology (K.-C.Y.), Graduate Institute of Clinical Pharmacy & School of Pharmacy (F.-J.L.), and Graduate Institute of Brain and Mind Sciences (M.-J.C.), College of Medicine, National Taiwan University; Institute of Electro-Optical Science and Technology (J.-J.C.), National Taiwan Normal University; and Graduate Institute of Biomedical Engineering and Bioinformatics (M.-J.C.) and Graduate Institute of Psychology (M.-J.C.), National Taiwan University, Taipei.
Kai-Chien YangFrom the Department of Neurology (C.-H.L., C.-H.L., M.-J.C.), Department of Internal Medicine (K.-C.Y., C.-C.W.), and Department of Pharmacy (F.-J.L.), National Taiwan University Hospital, College of Medicine, National Taiwan University; Department of Pharmacology (K.-C.Y.), Graduate Institute of Clinical Pharmacy & School of Pharmacy (F.-J.L.), and Graduate Institute of Brain and Mind Sciences (M.-J.C.), College of Medicine, National Taiwan University; Institute of Electro-Optical Science and Technology (J.-J.C.), National Taiwan Normal University; and Graduate Institute of Biomedical Engineering and Bioinformatics (M.-J.C.) and Graduate Institute of Psychology (M.-J.C.), National Taiwan University, Taipei.
Fang-Ju LinFrom the Department of Neurology (C.-H.L., C.-H.L., M.-J.C.), Department of Internal Medicine (K.-C.Y., C.-C.W.), and Department of Pharmacy (F.-J.L.), National Taiwan University Hospital, College of Medicine, National Taiwan University; Department of Pharmacology (K.-C.Y.), Graduate Institute of Clinical Pharmacy & School of Pharmacy (F.-J.L.), and Graduate Institute of Brain and Mind Sciences (M.-J.C.), College of Medicine, National Taiwan University; Institute of Electro-Optical Science and Technology (J.-J.C.), National Taiwan Normal University; and Graduate Institute of Biomedical Engineering and Bioinformatics (M.-J.C.) and Graduate Institute of Psychology (M.-J.C.), National Taiwan University, Taipei.
Chau-Chung WuFrom the Department of Neurology (C.-H.L., C.-H.L., M.-J.C.), Department of Internal Medicine (K.-C.Y., C.-C.W.), and Department of Pharmacy (F.-J.L.), National Taiwan University Hospital, College of Medicine, National Taiwan University; Department of Pharmacology (K.-C.Y.), Graduate Institute of Clinical Pharmacy & School of Pharmacy (F.-J.L.), and Graduate Institute of Brain and Mind Sciences (M.-J.C.), College of Medicine, National Taiwan University; Institute of Electro-Optical Science and Technology (J.-J.C.), National Taiwan Normal University; and Graduate Institute of Biomedical Engineering and Bioinformatics (M.-J.C.) and Graduate Institute of Psychology (M.-J.C.), National Taiwan University, Taipei.
Jen-Jie ChiehFrom the Department of Neurology (C.-H.L., C.-H.L., M.-J.C.), Department of Internal Medicine (K.-C.Y., C.-C.W.), and Department of Pharmacy (F.-J.L.), National Taiwan University Hospital, College of Medicine, National Taiwan University; Department of Pharmacology (K.-C.Y.), Graduate Institute of Clinical Pharmacy & School of Pharmacy (F.-J.L.), and Graduate Institute of Brain and Mind Sciences (M.-J.C.), College of Medicine, National Taiwan University; Institute of Electro-Optical Science and Technology (J.-J.C.), National Taiwan Normal University; and Graduate Institute of Biomedical Engineering and Bioinformatics (M.-J.C.) and Graduate Institute of Psychology (M.-J.C.), National Taiwan University, Taipei.
Ming-Jang ChiuFrom the Department of Neurology (C.-H.L., C.-H.L., M.-J.C.), Department of Internal Medicine (K.-C.Y., C.-C.W.), and Department of Pharmacy (F.-J.L.), National Taiwan University Hospital, College of Medicine, National Taiwan University; Department of Pharmacology (K.-C.Y.), Graduate Institute of Clinical Pharmacy & School of Pharmacy (F.-J.L.), and Graduate Institute of Brain and Mind Sciences (M.-J.C.), College of Medicine, National Taiwan University; Institute of Electro-Optical Science and Technology (J.-J.C.), National Taiwan Normal University; and Graduate Institute of Biomedical Engineering and Bioinformatics (M.-J.C.) and Graduate Institute of Psychology (M.-J.C.), National Taiwan University, Taipei. mjchiu@ntu.edu.tw.
National Taiwan University Hospital · TWNational Taiwan Normal University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo examine whether plasma neurofilament light chain (NfL) levels were associated with motor and cognitive progression in Parkinson disease (PD).

methodsThis prospective follow-up study enrolled 178 participants, including 116 with PD, 22 with multiple system atrophy (MSA), and 40 healthy controls. We measured plasma NfL levels with electrochemiluminescence immunoassay. Patients with PD received evaluations of motor and cognition at baseline and at a mean follow-up interval of 3 years. Changes in the Unified Parkinson's Disease Rating Scale (UPDRS) part III motor score and Mini-Mental State Examination score were used to assess motor and cognition progression.

resultsPlasma NfL levels were significantly higher in the MSA group than in the PD and healthy groups (35.8 ± 6.2, 17.6 ± 2.8, and 10.6 ± 2.3 pg/mL, respectively,

conclusionsPlasma NfL levels correlated with disease severity and progression in terms of both motor and cognitive functions in PD. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that plasma NfL level distinguishes PD from MSA and is a surrogate biomarker for PD progression.

Indexed as

Disease ProgressionSeverity of Illness IndexAgedBiomarkersFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleMiddle AgedNeurofilament ProteinsParkinson DiseaseProspective StudiesBiomarkersneurofilament protein LNeurofilament Proteins

Identifiers

PMID31420461
OpenAlexW2967878847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.